Loading...
FDA Approvals And Rising API Demand Will Drive Margin Expansion Over The Long Term
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
16 Dec 25
Views
18
16 Dec
₹548.10
AnalystConsensusTarget's Fair Value
₹566.00
3.2% undervalued intrinsic discount1Y
15.0%7D
-5.5%1Y
15.0%7D
-5.5%You can edit this narrative until Dec 17 2:05 AM. Then, changes will post as Updates.
Author's Valuation
₹5663.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value